The Central Drugs Standard Control Organisation in India is inviting public contributions concerning new regulations aimed at curbing the sale of various medications under similar brand names, which can mislead both patients and pharmacists about their contents. As part of this initiative, the drug regulator has released a notice for stakeholder observations, with a deadline for comments set for July 17 to ensure improved safety and trust among patients.